Novo Nordisk's weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...

Oral ivarmacitinib, administered 4 mg or 8 mg once daily, significantly induced hair regrowth at 24 weeks vs. placebo in ...

Pfizer said that Litfulo (ritlecitinib) is the first alopecia areata therapy to be cleared for use in adolescents in the EU. JAK1/2 inhibitor Olumiant (baricitinib) was the first drug to be ...

Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition that affects around ...

A new drug that works against the main types of primary bone cancer has been developed by researchers at the University of ...

Litfulo is one of seven new medicines approved ... Other treatments include drugs for a heart condition, cancer and insomnia. The support group Alopecia UK welcomed the announcement to give ...

Thirty-six weeks of once-daily, oral baricitinib was associated with greater hair regrowth on the scalp, eyebrows and ...

When diagnosing drug-induced alopecia, a doctor will take a complete medical history that takes into account the following factors: any new medications that the person is taking, including over ...

Olumiant (baricitinib) is a prescription drug used to treat severe alopecia areata. It’s typically used when hair loss from this condition affects more than 50% of the scalp. Olumiant is a brand ...

Alopecia refers to hair loss and can affect the scalp, eyebrows, eyelashes, and other areas of the body. There are different types of alopecia including androgenetic alopecia, alopecia areata, anagen ...

Frontal fibrosing alopecia (FFA) is a highly distressing ... while exploring the potential of targeting ERAP1 with highly specific drugs as a new way of treating this condition.